DelveInsight’s “Pheochromocytoma Market Insights, Epidemiology, and Market Forecast-2032” report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as Pheochromocytoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key facts of the Pheochromocytoma Market Report:
- Catecholamine-secreting tumors are rare neoplasms, occurring in less than 0.2 percent of patients with hypertension.
- The annual incidence of pheochromocytoma is estimated to be approximately 0.8 per 100,000 person-years. However, it is underestimated as 50 percent of pheochromocytomas are diagnosed at autopsy in one series.
- Although pheochromocytomas may occur at any age, they are most common in the fourth to fifth decade and are equally common in males and females.
- Most catecholamine-secreting tumors are sporadic. However, approximately 40 percent of patients have the disease as part of a familial disorder; in these patients, the catecholamine-secreting tumors are more likely to be bilateral adrenal pheochromocytomas or paragangliomas.
Request for Sample Report: https://www.delveinsight.com/sample-request/pheochromocytoma-market
Key benefits of the Pheochromocytoma Market report:
- The study provides a detailed review of Pheochromocytoma, including its causes, signs and symptoms, pathophysiology, diagnosis, and current treatments.
- Study of the 7MM has offered comprehensive insight into the epidemiology and management of Pheochromocytoma.
- Furthermore, an all-inclusive description of both present and emerging Pheochromocytoma treatments is offered, as well as an analysis of future therapies that will have an influence on the current treatment landscape.
- The research includes a full evaluation of the Pheochromocytoma market, both historical and anticipated, as well as drug outreach in the 7MM population.
- By understanding the trends defining and driving the worldwide Pheochromocytoma market, the study gives you an advantage when formulating business plans.
Pheochromocytoma Overview
Pheochromocytoma are adrenal gland tumors that produce an excess of adrenaline (also referred to catecholamines; epinephrine, metanephrine, and dopamine). Pheochromocytomas originate from the adrenal medulla, which is the core section of the adrenal gland. The adrenal medulla is in charge of the body’s natural production of adrenaline, which is needed to assist regulate blood pressure and cope with stressful conditions. A pheo is a tumor that develops from the adrenal medulla and overproduces adrenaline. It can be fatal due to the significant spike in blood pressure it generates.
Signs and symptoms of pheochromocytomas often include:
- High blood pressure
- Headache
- Heavy sweating
- Rapid heartbeat
- Tremors
- Paleness in the face
- Shortness of breath
- Panic attack-type symptoms
Researchers aren’t sure what causes pheochromocytoma. The tumour grows in specialized cells known as chromaffin cells, which are found in the middle of an adrenal gland. These cells release certain hormones, primarily adrenaline (epinephrine) and noradrenaline (norepinephrine), that help control many body functions, such as heart rate, blood pressure and blood sugar.
The report’s Pheochromocytoma market outlook assists in developing a detailed understanding of historic, current, and forecasted Pheochromocytoma market trends by analyzing the impact of current Pheochromocytoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This section examines the Pheochromocytoma market trend of each marketed drug and late stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing market need, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, market impact, and key opinion leaders’ perspectives. Pheochromocytoma market statistics are supplied with pertinent tables and graphs to provide a comprehensive picture of the market at a glance. According to DelveInsight, the Pheochromocytoma market in 7MM is expected to undergo significant change between 2019 and 2032.
Learn more by requesting for sample @ Pheochromocytoma Market Landscape
Pheochromocytoma Companies
- GE Healthcare
- Merck Sharp & Dohme Corp.
- Molecular Insight Pharmaceuticals, Inc.
- Enterome
- Antonio Fojo
- Ipsen
- Pfizer
- Roche Pharma AG
- And Many More
Pheochromocytoma Pipeline
- 123I-mIBG (metaiodobenzylguanidine)
- Belzutifan
- Ultratrace Iobenguane
- EO2401
- Lanreotide
- Axitinib
- Sunitinib
- Cabozantinib
- And Many More
Table of Contents
1. Key Insights
2. Executive Summary of Pheochromocytoma
3. Competitive Intelligence Analysis for Pheochromocytoma
4. Pheochromocytoma: Market Overview at a Glance
5. Pheochromocytoma: Disease Background and Overview
6. Patient Journey
7. Pheochromocytoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Pheochromocytoma Unmet Needs
10. Key Endpoints of Pheochromocytoma Treatment
11. Pheochromocytoma Marketed Products
12. Pheochromocytoma Emerging Therapies
13. Pheochromocytoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Pheochromocytoma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/